Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue 10, 2012, Pages 1079-1083

  Joutsa, Juho ^a   Martikainen, Kirsti ^b   Vahlberg, Tero ^c   Kaasinen, Valtteri ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b The Finnish Parkinson Association and the Finnish Parkinson Foundation   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Depression; Dopamine agonist; Follow up; Parkinson's disease

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PRAMIPEXOLE; ROPINIROLE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; GENDER; HUMAN; IMPULSE CONTROL DISORDER; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; AMANTADINE; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; DATA COLLECTION; DEPRESSION; DISEASE PROGRESSION; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; LEVODOPA; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SELF REPORT; SEX DISTRIBUTION;

EID: 84870481093     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.06.005     Document Type: Article

References (22)

1. Ambermoon P., Carter A., Hall W.D., Dissanayaka N.N., O'Sullivan J.D. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 2011, 106:283-293.
2. Voon V., Schoerling A., Wenzel S., Ekanayake V., Reiff J., Trenkwalder C., et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol 2011, 11:117.
3. Mamikonyan E., Siderowf A.D., Duda J.E., Potenza M.N., Horn S., Stern M.B., et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008, 23:75-80.
4. Macphee G.J., Copeland C., Stewart D., Grosset K., Grosset D.G. Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Mov Disord 2009, 24:2430-2431.
5. Sohtaoĝlu M., Demiray D.Y., Kenangil G., Ozekmekçi S., Erginöz E. Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2010, 16:334-337.
6. Bharmal A., Lu C., Quickfall J., Crockford D., Suchowersky O. Outcomes of patients with Parkinson disease and pathological gambling. Can J Neurol Sci 2010, 37:473-477.
7. Singh A., Kandimala G., Dewey R.B., O'Suilleabhain P. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci 2007, 14:1178-1181.
8. Weintraub D., Sohr M., Potenza M.N., Siderowf A.D., Stacy M., Voon V., et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010, 68:963-968.
9. Weintraub D., Koester J., Potenza M., Siderowf A., Stacy M., Voon V., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010, 67:589-595.
10. Ahlskog J.E. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiol Behav 2011, 104:168-172.
11. Joutsa J., Martikainen K., Vahlberg T., Voon V., Kaasinen V. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord 2012, 18:155-160.
12. Rabinak C.A., Nirenberg M.J. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010, 67:58-63.
13. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010, 25:2649-2653.
14. Weintraub D., Hoops S., Shea J., Lyons K., Pahwa R., Driver-Dunckley E., et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2009, 24:1461-1467.
15. Papay K., Mamikonyan E., Siderowf A.D., Duda J.E., Lyons K.E., Pahwa R., et al. Parkinsonism Relat Disord 2011, 17:153-155.
16. Gallagher D.A., O'Sullivan S.S., Evans A.H., Lees A.J., Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007, 22:1757-1763.
17. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005, 62:1377-1381.
18. Voon V., Sohr M., Lang A.E., Potenza M.N., Siderowf A.D., Whetteckey J., et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol 2011, 69:986-996.
19. Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., Ahlskog J.E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005, 11:381-386.
20. Knipe M.D., Wickremaratchi M.M., Wyatt-Haines E., Morris H.R., Ben-Shlomo Y. Quality of life in young- compared with late-onset Parkinson's disease. Mov Disord 2011, 26:2011-2018.
21. Limotai N., Oyama G., Go C., Bernal O., Ong T., Moum S.J., et al. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience. Int J Neurosci 2012, 122:145-153.
22. Schrag A., Barone P., Brown R.G., Leentjens A.F., McDonald W.M., Starkstein S., et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007, 22:1077-1092.